A Phase 1 interventional study of Apixaban and Boost Plus in Healthy Subjects, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-06-23.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the bioavailability of Apixaban oral solution administered through an Nasogastric Tube (NGT) in the presence of Boost® Plus and Apixaban administered as crushed tablet through a nasogastric tube relative to Apixaban solution administered orally in healthy subjects.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Solution Apixaban 5 mg ( 0.4 mg/ml oral solution x 12.5 ml) through mouth or oral syringe
Drug: Apixaban
Oral Solution Apixaban 5 mg single dose (0.4 mg/mL oral solution x 12.5 mL) after 180 mL of Boost Plus®, followed by 60 mL of Boost Plus® via same NGT
Drug: Apixaban · Dietary Supplement: Boost Plus
Single dose crushed Apixaban tablet 5 mg (5 mg tablet crushed and suspended in 60 mL Dextrose 5% in water (D5W)) through NGT
Drug: Apixaban
Also known as: BMS-562247
Adjusted Geometric Mean of the Maximum Observed Plasma Concentration (Cmax) of Apixaban
Maximum observed plasma concentration (Cmax) is measured in nanograms per milliliter (ng/mL)
Time frame: Pre-dose and 0.25, 0.50, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, 72 hours post-dose for each intervention
Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero Extrapolated to Infinite Time AUC(INF) of Apixaban
AUC(INF) is measured in nanogram hours per milliliter (ng\*h/mL)
Time frame: Pre-dose and 0.25, 0.50, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, 72 hours post-dose for each intervention
Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-T)] of Apixaban
AUC(0-T) is measured in nanogram hours per milliliter (ng\*h/mL)
Time frame: Pre-dose and 0.25, 0.50, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, 72 hours post-dose for each intervention
Adjusted Geometric Mean of the Maximum Observed Plasma Concentration (Cmax) of Apixaban
Maximum observed plasma concentration (Cmax) is measured in nanograms per milliliter (ng/mL)
Time frame: Pre-dose and 0.25, 0.50, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, 72 hours post-dose for each intervention
Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time [AUC(INF)] of Apixaban
AUC(INF) is measured in nanogram hours per milliliter (ng\*h/mL)
Time frame: Pre-dose and 0.25, 0.50, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, 72 hours post-dose for each intervention
Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-T)] of Apixaban
AUC(0-T) is measured in nanogram hours per milliliter (ng\*h/mL)
Time frame: Pre-dose and 0.25, 0.50, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, 72 hours post-dose for each intervention
Number of Participants With Serious Adverse Events (SAEs), Treatment-Related AEs, Deaths or Discontinuation of Study Drug Due to AEs
AE=any new unfavorable symptom, sign or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity or drug dependency/abuse; is life-threatening, an important medical event or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible or missing relationship to study drug. Death=during the study and up to 28 days past study discontinuation. The select AEs were determined using the Medical Dictionary for Regulatory Activities (MedDRA, v15.1) and graded using the Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0
Time frame: Day 1 to 30 days after last dose of study drug
Number of Participants With Marked Laboratory Abnormalities
Marked laboratory abnormalities were defined as laboratory assessments meeting the following investigator-specified criteria: Leukocytes \>1.2\* upper limits of normal (ULN) , Basophils \>3%, Eosinophils \>1.5\*ULN, Blood Urine \>=2, Red Blood Cell (RBC) Urine \>=2, White Blood Cell (WBC) Urine \>=2
Time frame: Day 1 to 30 days after last dose of study drug
| Milestone | Treatment A, Then Treatment B, Then Treatment C | Treatment A, Then Treatment C, Then Treatment B | Treatment B, Then Treatment A, Then Treatment C | Treatment B, Then Treatment C, Then Treatment A | Treatment C, Then Treatment A, Then Treatment B | Treatment C, Then Treatment B, Then Treatment A |
|---|---|---|---|---|---|---|
| Started | 4 | 3 | 4 | 3 | 4 | 3 |
| Completed | 4 | 3 | 4 | 3 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 0 |
Maximum observed plasma concentration (Cmax) is measured in nanograms per milliliter (ng/mL)
| ng/mL | Treatment A | Treatment B |
|---|---|---|
| Adjusted Geometric Mean of the Maximum Observed Plasma Concentration (Cmax) of Apixaban | 179.116 (164.855 to 194.611) | 122.145 (112.011 to 133.196) |
AUC(INF) is measured in nanogram hours per milliliter (ng\*h/mL)
| ng*h/mL | Treatment A | Treatment B |
|---|---|---|
| Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero Extrapolated to Infinite Time AUC(INF) of Apixaban | 1397.666 (1330.658 to 1468.049) | 1136.380 (1065.716 to 1211.729) |
AUC(0-T) is measured in nanogram hours per milliliter (ng\*h/mL)
| ng*h/mL | Treatment A | Treatment B |
|---|---|---|
| Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-T)] of Apixaban | 1372.836 (1306.240 to 1442.828) | 1112.493 (1041.751 to 1188.038) |
Maximum observed plasma concentration (Cmax) is measured in nanograms per milliliter (ng/mL)
| ng/mL | Treatment A | Treatment C |
|---|---|---|
| Adjusted Geometric Mean of the Maximum Observed Plasma Concentration (Cmax) of Apixaban | 179.116 (164.855 to 194.611) | 158.371 (145.849 to 171.968) |
AUC(INF) is measured in nanogram hours per milliliter (ng\*h/mL)
| ng*h/mL | Treatment A | Treatment C |
|---|---|---|
| Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time [AUC(INF)] of Apixaban | 1397.666 (1330.658 to 1468.049) | 1327.248 (1246.871 to 1412.806) |
AUC(0-T) is measured in nanogram hours per milliliter (ng\*h/mL)
| ng*h/mL | Treatment A | Treatment C |
|---|---|---|
| Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-T)] of Apixaban | 1372.836 (1306.240 to 1442.828) | 1300.728 (1220.374 to 1386.374) |
AE=any new unfavorable symptom, sign or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity or drug dependency/abuse; is life-threatening, an important medical event or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible or missing relationship to study drug. Death=during the study and up to 28 days past study discontinuation. The select AEs were determined using the Medical Dictionary for Regulatory Activities (MedDRA, v15.1) and graded using the Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0
| participants | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| SAE | 0 | 0 | 1 |
| Treatment-Related AE | 0 | 1 | 1 |
| Deaths | 0 | 0 | 0 |
| Treatment-Related Deaths | 0 | 0 | 0 |
| Discontinuation of Study Drug Due to AEs | 0 | 0 | 0 |
Marked laboratory abnormalities were defined as laboratory assessments meeting the following investigator-specified criteria: Leukocytes \>1.2\* upper limits of normal (ULN) , Basophils \>3%, Eosinophils \>1.5\*ULN, Blood Urine \>=2, Red Blood Cell (RBC) Urine \>=2, White Blood Cell (WBC) Urine \>=2
| participants | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Leukocytes | 0 | 1 | 0 |
| Basophils | 1 | 0 | 0 |
| Eosinophils | 0 | 1 | 0 |
| Blood, Urine | 1 | 1 | 0 |
| RBC, Urine | 0 | 2 | 1 |
| WBC, Urine | 0 | 2 | 1 |
Collected over Day 1 to 30 days after last dose of study drug. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A | — | 0/20 (0%) | 6/20 (30%) |
| Treatment B | — | 0/20 (0%) | 3/20 (15%) |
| Treatment C | — | 1/21 (4.8%) | 1/21 (4.8%) |
| Event | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| GastritisGastrointestinal disorders | 0/20 | 0/20 | 1/21 |
| Event | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| HaematomaVascular disorders | 0/20 | 1/20 | 0/21 |
| PyuriaRenal and urinary disorders | 1/20 | 0/20 | 0/21 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/20 | 0/20 | 0/21 |
| HeadacheNervous system disorders | 1/20 | 1/20 | 1/21 |
| Vision blurredEye disorders | 1/20 | 0/20 | 0/21 |
| Rash macularSkin and subcutaneous tissue disorders | 1/20 | 0/20 | 0/21 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 1/20 | 0/20 | 0/21 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/20 | 1/20 | 0/21 |
| Rash papularSkin and subcutaneous tissue disorders | 0/20 | 1/20 | 0/21 |
All randomized participants
| Age, Continuous(years) | All Treatment Groups |
|---|---|
| Mean | 36.7 (22 to 45) |
| Sex: Female, Male(Participants) | All Treatment Groups |
|---|---|
| Female | 8 |
| Male | 13 |
The record gives a start of Oct 2011, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2016, 4 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apixaban